Trøseid, M. Et Al. 2023. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Critical Care , vol.27, no.1 .

Trøseid, M., Arribas, J. R., Assoumou, L., Holten, A. R., Poissy, J., Terzić, V., ... Mazzaferri, F.(2023). Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial. Critical Care , vol.27, no.1.

Trøseid, Marius Et Al. "Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial," Critical Care , vol.27, no.1, 2023

Trøseid, Marius Et Al. "Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial." Critical Care , vol.27, no.1, 2023

Trøseid, M. Et Al. (2023) . "Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial." Critical Care , vol.27, no.1.

@article{article, author={Marius Trøseid Et Al. }, title={Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial}, journal={Critical Care}, year=2023}